Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Endocrinology | Family Medicine | Geriatrics | Internal Medicine | Critical Care | Emergency Medicine | Surgery | Journal

Back to Journal Articles

Drug-Eluting Stents Lead to Fewer Adverse Cardiac Events

Last Updated: August 21, 2012.

 

Lower rates of major adverse cardiac events at one year, compared to bare-metal stents

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Among ST-segment elevation myocardial infarction patients, the use of biolimus-eluting stents with biodegradable polymer results in a lower rate of major adverse cardiac events, compared with patients with bare-metal stents, at one year following primary percutaneous coronary intervention, according to a study published in the Aug. 22/29 issue of the Journal of the American Medical Association.

TUESDAY, Aug. 21 (HealthDay News) -- Among ST-segment elevation myocardial infarction (STEMI) patients, the use of biolimus-eluting stents with biodegradable polymer results in a lower rate of major adverse cardiac events, compared with patients with bare-metal stents, at one year following primary percutaneous coronary intervention (PCI), according to a study published in the Aug. 22/29 issue of the Journal of the American Medical Association.

Lorenz Räber, M.D., from the Bern University Hospital in Switzerland, and colleagues conducted a prospective, single-blinded, controlled trial, in which 1,161 STEMI patients at 11 sites in Europe and Israel (Sept. 19, 2009, to Jan. 25, 2011) were randomized (1:1) to receive the biolimus-eluting stent (575 patients) or the bare-metal stent (582 patients).

The researchers found that, at one year, 24 patients (4.3 percent) receiving biolimus-eluting stents with biodegradable polymer had major adverse cardiac events, as did 49 patients (8.7 percent) receiving bare-metal stents (hazard ratio [HR], 0.49). A significantly lower risk of target vessel-related reinfarction (0.5 versus 2.7 percent; HR, 0.20) and ischemia-driven target-lesion revascularization (1.6 versus 5.7 percent; HR, 0.28) in patients receiving biolimus-eluting stents, compared with those receiving bare-metal stents, drove the difference in adverse cardiac events. Cardiac death rates were not significantly different between the groups (2.9 versus 3.5 percent).

"Compared with a bare-metal stent, the use of biolimus-eluting stents with a biodegradable polymer resulted in a lower rate of the composite of major adverse cardiac events at one year among patients with STEMI undergoing primary PCI," the authors write.

Several authors disclosed financial ties to the pharmaceutical and biomedical industries.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Meta-Analysis Links Statins to Reduced Pancreatitis Risk Next: T Cells Key in Atherosclerosis-Linked Inflammation

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.